Symptoms compatible with irritable bowel syndrome (IBS) are common in patients with inflammatory bowel disease (IBD), but it is unclear whether this relates to occult IBD activity. We attempted to resolve this issue in a secondary care population by using a cross-sectional study design.
Because CD and UC are lifelong conditions without cure, there is the potential for patients to be faced with many years of chronic GI symptoms, and because IBS is a highly prevalent condition, it is also plausible that a proportion of these symptoms may be a result of coexistent IBS. A recent systematic review and meta-analysis of studies reporting IBS-type symptoms in IBD suggested an overall prevalence between 35% and 44%. 4 However, among the 13 included studies, only 2 assessed for evidence of ongoing disease activity among those who reported these symptoms 5, 6 by using fecal calprotectin (FC). The number of included patients in both studies was relatively small, and the results were conflicting.
This issue has important implications for clinical practice, because there may be considerable difficulty in distinguishing genuine functional symptoms in IBD from those caused by ongoing occult inflammation because of the lack of immediate access to the results of diagnostic tests to differentiate between the two in the outpatient clinic. This could result in unnecessary invasive endoscopic investigations or inappropriate escalation of therapy to either immunosuppressants or biologics in patients with functional symptoms, when in fact, other management strategies are required.
Therefore, we have examined this issue in a large cohort of IBD patients by using FC as an objective measure of disease activity and the Rome III criteria for IBS to assess the true magnitude of this problem. Our hypothesis was that there is a subset of IBD patients with genuine IBS-type symptoms, and that these symptoms would impact negatively on psychological health and quality of life, which, if proven, may serve as a mandate for treatment trials in this challenging group of patients to resolve continuing uncertainty surrounding how best to manage them.
Methods

Participants and Setting
All individuals who participated had an established radiologic, histologic, or endoscopic diagnosis of CD or UC. Unselected consecutive patients aged 16 years attending the IBD clinic at St James's University Hospital, Leeds, United Kingdom, which serves a local population of 800,000 people, were approached about the study. Exclusion criteria were an inability to understand written English, a diagnosis of IBD-unclassified, isolated fistulizing perianal CD, or anyone with an end ileostomy or colostomy because of the difficulties in assessing disease activity indices in these patients. At the clinic attendance before the consultation with a gastroenterologist, individuals were presented with an information sheet explaining the nature of the study. Those who agreed to take part provided written informed consent at this visit. The study was approved by the local research ethics committee in November 2012, and data collection continued until June 2015. Data collection and synthesis are described in detail in the Supplementary Methods.
Statistical Analysis
We compared baseline demographic characteristics, prevalence of IBS-type symptoms, disease activity, hospital anxiety and depression scale (HADS) scores, patient health questionnaire (PHQ)-15 scores, short form-36 (SF-36) scores, and presence or absence of anxiety, depression, or somatization between patients with CD and UC by using a c 2 test for categorical variables and an independent samples t-test for continuous data.
After classification of disease activity and IBS-type symptom status by using a cutoff of <250 mg/g of stool to define no evidence of mucosal inflammation, we compared baseline demographic characteristics, HADS scores, PHQ-15 scores, SF-36 scores, and presence or absence of anxiety, depression, or somatization between those with true IBS-type symptoms and the other 3 groups of patients individually (quiescent disease, occult inflammation, or active disease) by using a c 2 test for categorical variables and an independent samples t test for continuous data, as well as across all 4 groups by using a c 2 test for categorical variables and a one-way analysis of variance (ANOVA) for continuous data. We repeated these comparisons between the same 4 categories but used FC <100 mg/g to define no evidence of mucosal inflammation (Supplementary Results). Because of multiple comparisons a 2-tailed P value <.01 was considered to be statistically significant for all analyses. All statistical analyses were performed by using SPSS for Windows version 21.0 (SPSS Inc, Chicago, IL).
Results
In total, 378 patients with IBD provided informed consent to participate and had complete data. Of these, 206 (54.5%) had confirmed CD, and 172 (45.5%) had UC. Characteristics of UC and CD patients are provided in Table 1 . There were 144 patients with IBD (38.1%) who reported symptoms compatible with IBS, 92 with CD (44.7%), and 52 with UC (30.2%) (P ¼ .004). In terms of disease activity, 128 of those with CD (62.1%) had Harvey-Bradshaw (HBI) <5, and 103 of those with UC (59.9%) had simple clinical colitis activity index (SCCAI) <5. Patients with CD were slightly younger, more likely to smoke, less likely to be using mesalamine, more likely to be using immunosuppressants or anti-tumor necrosis factor-a (TNFa) drugs, and scored lower in some domains of the SF-36 such as energy/fatigue, pain, and general health. (Figure 1 ). Therefore, after FC analysis, 57 of 92 patients (62.0%) who met criteria for IBS had no evidence of active disease or occult inflammation and had true IBS-type symptoms, whereas 31 of 78 (39.7%) with HBI 5 had genuinely active disease, and 32 (41.0%) were reclassified as having IBS-type symptoms.
Effect of Fecal Calprotectin
There were significantly more female patients among those with true IBS-type symptoms and those with active disease, compared with the other 2 groups, and also more tobacco users among those with true IBS-type symptoms compared with those with quiescent CD, but there were no other differences in demographic characteristics (Table 2 ). Of note was that mean anxiety, depression, and somatization scores were all significantly higher in CD with true IBS-type symptoms compared with patients with either quiescent CD or CD with occult inflammation, but they were similar to those in patients with active CD. There were also more patients who met criteria for somatization in the CD with true IBS-type symptoms group than those with either quiescent CD or CD with occult inflammation, but an almost identical proportion among those with active CD. Quality of life scores across all 8 domains of SF-36 were Figure 2 ). Therefore, after FC analysis, 34 of 52 patients (65.4%) who met criteria for IBS had no evidence of active disease or occult inflammation and had true IBS-type symptoms, whereas 36 of 69 (52.2%) with SCCAI 5 had genuinely active disease, and 18 (26.1%) were reclassified as having IBS-type symptoms.
There were no differences in demographic characteristics between the 4 groups, but mean anxiety, depression, and somatization scores were all significantly higher in those with true IBS-type symptoms, compared with those with either quiescent UC or occult inflammation, and anxiety scores were also significantly higher than in those with active UC (Table 3 ). There were also significantly more patients who met criteria for anxiety, depression, or somatization in the group with true IBS-type symptoms than among those with either quiescent UC or UC with occult inflammation. Mean quality of life scores were significantly lower in patients with true IBS-type symptoms compared with quiescent UC patients for all domains of the SF-36 except physical functioning and all domains except physical functioning, role limitations due to physical health, and energy/fatigue when compared with UC with occult inflammation. Again, quality of life scores were impaired to a similar degree to those with active UC.
Discussion
This cross-sectional study has demonstrated an overall prevalence of IBS-type symptoms in outpatients with IBD between 30% and 45%, with symptoms more commonly observed in patients with CD than UC. After using FC analysis to minimize the likelihood of ongoing mucosal inflammation, approximately two-thirds of patients who met criteria for IBS were still believed to have genuine IBS-type symptoms rather than occult inflammation or active disease, and between 26% and 41% of those who reported symptoms compatible with active disease were reclassified as having IBS-type symptoms. Among both CD and UC patients with true IBS-type symptoms there was substantial psychological comorbidity, with the prevalence and severity of anxiety, depression, and somatization all higher than among patients with either quiescent disease or occult inflammation. In addition, the reduction in quality of life associated with the presence of these symptoms was consistently greater than that observed in CD and UC patients with quiescent disease or occult inflammation and was of a similar magnitude to those with active disease. It may be that the presence of any GI symptoms in the absence of objective evidence of mucosal inflammation, including those incorporated in the clinical disease activity indices we used, is associated with poor psychological health and reduced quality of life, but this issue was not one our study aimed to examine.
Strengths of this study include the fact that we recruited a well-characterized group of consecutive unselected patients, collecting data on both presence of IBStype symptoms and disease activity indices, as well as using FC as an objective quantitative measure of disease activity, to categorize patients into those with true IBS-type symptoms, quiescent disease, occult inflammation, or active disease. FC is known to correlate well with endoscopic disease activity scores, 7 and more recently it has been identified as a useful marker of small bowel inflammation in CD, when compared with magnetic resonance enterography. 8 Our sample size of 378 patients is larger than previous studies examining this issue, 5, 6 and the fact that the study was conducted in a secondary care clinic means that our results are likely to be generalizable to usual clinical practice. Finally, we used validated questionnaires to assess for presence of anxiety or depression, somatization, quality of life, and the presence of IBS-type symptoms, albeit that the Rome III questionnaire has not been validated for use in patients with IBD. However, recent work from our group suggests that endorsement of these criteria correlates with higher clinical disease activity indices, which themselves appear to correlate with somatoform-type symptom reporting in both CD and UC. 9 Because this was a cross-sectional study, an obvious weakness is that causality cannot be implied by our results. Furthermore, 1 in 3 CD patients had undergone intestinal resection previously, and because bile acid diarrhea or small intestinal bacterial overgrowth may occur as a result of surgery 10, 11 and there is overlap between the symptoms of these conditions and those of IBS, 12, 13 it is possible that we have overestimated the prevalence of IBS. In addition, gold-standard investigations for IBD activity, including small bowel imaging and ileocolonoscopy, were not performed routinely because the study was conducted within usual clinical practice. This means that we cannot exclude the fact that there was ongoing mucosal inflammation or, in those with CD, occult fibrostenotic small bowel disease in some individuals who met criteria for IBS, although no difference in disease behavior was observed across the 4 groups. However, only 24% of included patients with CD and IBS-type symptoms had isolated small bowel disease, and even when we used FC cutoff <100 mg/g, 18% of those with CD and 11% of those with UC still had true IBS-type symptoms. There were fewer statistically significant differences between groups when FC cutoff <100 mg/g was used, although this was likely due to a reduction in the size of the groups of individuals with either true IBS-type symptoms or quiescent disease. When analyses that used this cutoff were repeated for CD and UC patients together, the differences in psychological comorbidity and quality of life in those with IBS-type symptoms became statistically significant once again. The lack of a control group meant that we could not compare the impact of IBS-type symptoms on psychological health and quality of life in patients with IBD with that in patients with confirmed IBS. Finally, we did not collect data delineating the brain-gut constructs involved in the generation of IBS-type symptoms in patients with IBD, which may have allowed exploration of the mechanisms by which these symptoms occur.
Several studies have investigated the prevalence of IBS-type symptoms in patients with IBD and their association with psychological comorbidity. However, to our knowledge, only 2 have used an objective measure of mucosal inflammation. 5, 6 Keohane et al 5 assessed the prevalence of IBS-type symptoms and their impact on quality of life and depression scores in 106 IBD patients and found that 60% of CD patients and 39% of UC patients in clinical remission met the Rome II criteria for IBS. Quality of life scores were lower and depression scores were higher in UC, but not CD, patients with IBStype symptoms versus those without. However, FC levels were significantly higher among patients meeting Rome II criteria, suggesting that the mechanism for these symptoms was occult inflammation rather than true IBS. In contrast, Berrill et al 6 recruited 169 IBD patients and reported that 32% of those in clinical remission reported IBS-type symptoms, again with higher anxiety and depression scores in the IBS group, with no differences in FC levels between those with and without IBS-type symptoms, but only 61 patients returned a stool sample. Although our findings suggest a similar prevalence of IBS-type symptoms in patients in clinical remission, these studies did not use FC levels to define a genuine subset of IBD patients with true IBS-type symptoms, and they were not large enough to explore the characteristics of this group. In addition, because the mean FC levels we observed in UC and CD patients with true IBS-type symptoms were very similar to those with quiescent disease, our findings do not support occult disease activity as the sole cause of these symptoms.
The etiology of functional symptoms in IBD remains uncertain and is likely to be multifactorial. Higher levels of peripheral and mucosal proinflammatory cytokines have been demonstrated in IBS patients, 14 and it may be that in IBD a low-grade inflammation, distinct from that of overt disease activity, leads to activation of the enteric nervous system, epithelial barrier dysfunction, increased mucosal permeability, visceral hypersensitivity, and activation of the brain-gut axis, resulting in the generation of IBS-type symptoms. The cause of this ongoing low-grade inflammation could be perturbations in the intestinal microbiome, with a relative abundance of proinflammatory bacterial species having been previously described in IBS. 15 Activation of the brain-gut axis may also be responsible for the development of psychological comorbidity. However, whether this arises de novo as a consequence of IBS-type symptoms or whether functional symptoms arise as a result of preexisting anxiety and depression is unclear. Evidence to support a bidirectional relationship between the brain and gut has been described in animal models of disease, where mice with chronic GI inflammation develop behavioral changes similar to mood disorders in humans, 16 and inducing depression in murine models of quiescent colitis results in reactivation of disease, 17 which may be attenuated by the administration of antidepressant medication. 18 Our data provide support for the same bidirectional effect in humans. Those with IBS-type symptoms and those with active disease had higher levels of anxiety, depression, and somatization compared with those with quiescent disease or occult inflammation. In the former group, this suggests a brain-gut direction of effect with psychological comorbidity leading to the generation of functional GI symptoms and in the latter group a gut-brain direction of effect with active inflammation leading to psychological symptoms. However, longitudinal studies examining the relationship between psychological health, disease activity, and presence of IBS-type symptoms will be needed to prove this hypothesis.
Our study has important implications for clinical practice. First, IBS-type symptoms are common, and with the increased use of biomarkers such as FC to monitor disease activity, the emergence of a cohort of patients with true IBS-type symptoms is likely to occur. Second, although escalation of conventional immunosuppressant and biological therapies has been advocated previously in these patients, 3 current data do not support the efficacy of such drugs when objective evidence of disease activity is lacking. 19 In addition, this approach may be expensive and could expose patients to potential unnecessary risks associated with these therapies. 20, 21 Despite this, there is a paucity of evidence for alternative approaches in this group of patients, and controlled trials of psychological and pharmacologic therapies, including antidepressants, as well as manipulation of the intestinal microbiota by probiotics or fecal microbial transfer may be required.
In summary, genuine IBS-type symptoms in IBD are common and are associated with higher levels of anxiety, depression, and somatization and reduced quality of life. Previous investigators have suggested that functional symptoms in IBD are a result of occult disease activity. However, our study has identified a distinct group of patients with ongoing GI symptoms in the absence of objective evidence of disease activity and demonstrates that the presence of these symptoms impacts negatively on both psychological well-being and quality of life to the same degree as active disease. The cause of these symptoms is uncertain, as is their effect on the natural history of IBD, and further longitudinal studies examining the relationship between disease activity, IBStype symptoms, and psychological comorbidity are warranted.
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Supplementary Methods
Data Collection and Synthesis
Demographic data and disease characteristics. Once informed consent was obtained, demographic data including gender, age, ethnicity, marital status, educational level, tobacco and alcohol use, weight (in kilograms) and height (in meters), which were used to calculate body mass index, were collected. Medication history, including current use of mesalamine, glucocorticosteroids, immunosuppressants, or anti-TNFa therapies, disease location and behavior for CD, or distribution for UC, as defined by the Montreal classification, 1 and any previous intestinal resection related to CD were also recorded.
At their clinic visit participants were asked to provide stool for quantitative FC analysis (Immundiagnostik, Bensheim, Germany), as an objective marker of mucosal inflammation, within 7 days of study entry. We used cutoff <250 mg/g of stool as the primary analysis to define no evidence of mucosal inflammation, in line with the European Crohn's and Colitis Organization consensus on the use of FC to measure disease activity, 2 as other investigators have used, [3] [4] [5] but using <100 mg/g in a secondary analysis.
Assessment of Inflammatory Bowel Disease Activity
Assessment of IBD activity was performed by using the HBI for CD 6 and the SCCAI for UC, 7 with a score <5 used to define clinical remission for both, as previously recommended. 8, 9 Reference Standard Used to Define Presence of Irritable Bowel Syndrome-type Symptoms
The presence or absence of IBS-type symptoms was assessed via the Rome III criteria, 10 according to the scoring algorithm proposed for use with the Rome III diagnostic questionnaire for adult functional GI disorders. IBS-type symptoms were defined as present when an individual reported abdominal discomfort or pain with a frequency of at least 2 or 3 days per month during the last 3 months, with the onset of discomfort at least 6 months previously, associated with 2 or more of the following: an improvement of pain or discomfort with the passage of stool, more or less frequent bowel movements, or looser or firmer stools.
Definition of Disease Activity and Presence of Irritable Bowel Syndrome-type Symptoms
By using a combination of disease activity indices, presence or absence of symptoms compatible with Rome III-defined IBS, and FC levels, we were able to categorize patients with UC or CD into 4 categories. Those who reported IBS-type symptoms with FC <250 mg/g were defined as having true IBS-type symptoms, regardless of disease activity indices. Those who did not report IBStype symptoms with FC <250 mg/g were defined as having quiescent disease, regardless of disease activity indices. Those with normal disease activity indices and FC 250 mg/g were defined as having occult inflammation, regardless of IBS symptom status. Finally, those with abnormal disease activity indices with FC 250 mg/g were defined as having active disease, regardless of whether they reported IBS-type symptoms. We also categorized patients in an identical manner by using FC <100 mg/g or 100 mg/g.
Definition of Anxiety or Depression
Anxiety and depression data were collected by using the HADS.
11 This 14-item questionnaire consists of 7 questions screening for the presence of anxiety symptoms and 7 for depression symptoms, with a 4-point response for each item ranging from 0 to 3. The total HADS score ranges from a minimum of 0 to a maximum of 21 for both anxiety and depression. Severity was categorized, according to total HADS score, into normal (total HADS depression or anxiety score 0-7), borderline normal (8-10), or abnormal (11).
11
Definition of Somatization Severity by Using the Patient Health Questionnaire-15
Somatization data were collected by using the PHQ-15, which is derived from the validated full PHQ.
12,13
The PHQ-15 inquires about the presence of 15 somatic symptoms (or symptom clusters) during the last 4 weeks, which contribute to >90% of physical complaints reported in the outpatient environment.
14 Each individual was asked to rate the severity of each symptom as "not bothered at all" (scored as 0), "bothered a little" (scored as 1), or "bothered a lot" (scored as 2). Therefore, the total PHQ-15 score ranges from a minimum of 0 to a maximum of 30. Somatization severity was categorized, by using the total PHQ-15 score, into high (total PHQ-15 15), medium (10-14), low (5-9), or minimal (4) levels of somatization severity.
Assessment of Quality of Life
The medical outcomes study SF-36 health survey, a validated questionnaire used to assess physical and mental health status, 15 was used to make an assessment of health-related quality of life. This comprises 36 questions that are grouped into 8 health domains (physical functioning, role limitations due to physical health, role limitations due to emotional health, energy or fatigue, emotional well-being, social functioning, pain, and general health). Patients were asked to complete the questionnaire by giving responses to each question from 0 to 100, from which a mean score for each health domain was calculated, with higher scores indicating more favorable health-related quality of life.
Supplementary Results
Effect of Fecal Calprotectin Analysis by Using
Cutoff <100 mg/g on Disease Activity Status and Characteristics of Inflammatory Bowel Disease Patients With and Without Irritable Bowel Syndrome-
type Symptoms
Results of comparisons between the 4 CD and UC groups by using FC cutoff <100 mg/g to define no evidence of mucosal inflammation were similar in terms of the magnitude of the differences in anxiety, depression, somatization, and quality of life scores seen among those with both true IBS-type symptoms and active disease, although because of a reduction in the size of the group of individuals with true IBS-type symptoms, there were fewer statistically significant differences (Supplementary  Tables 1 and 2 ). When analyses using this cutoff were repeated for all IBD patients combined, the differences in psychological comorbidity and quality of life in those with IBS-type symptoms became statistically significant once more (Supplementary Table 3 ). 
